Prevalence of growth retardation among children and adolescents in China: a systematic review and meta-analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The overall prevalence of growth delay in Chinese children and adolescents is 5.7%, with higher rates in younger children and rural areas. This prevalence is decreasing over time, indicating a need for continued public health efforts.
Area Of Science
- Pediatrics
- Public Health
- Epidemiology
Background
- Growth delay affects a significant number of children and adolescents.
- Understanding the prevalence and trends of growth delay is crucial for early intervention.
Purpose Of The Study
- To determine the prevalence of growth delay in Chinese children and adolescents using a meta-analysis.
- To provide scientific evidence for early intervention and prevention strategies.
Main Methods
- A meta-analysis was conducted on 50 studies involving 2,644,818 participants.
- Studies were retrieved from eight major databases and assessed for quality using STROBE guidelines.
- Data were analyzed using Stata 15.
Main Results
- The overall prevalence of growth delay was 5.7% (95% CI: 5.3%-6.2%).
- Prevalence varied by age (highest in 0-2 years at 7.4%) and residential area (higher in rural areas at 8.4%).
- Prevalence showed a decreasing trend over time, from 25.8% (2005-2009) to 3.0% (2020-2024).
Conclusions
- Growth delay prevalence in China is decreasing but shows significant variations across age groups and residential settings.
- Public health initiatives, healthy lifestyle promotion, and improved nutrition education are recommended.
- Strengthening the healthcare system is essential for managing and preventing growth delay.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...